Hubei Biocause Pharmaceutical
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ethe… Read more
Hubei Biocause Pharmaceutical - Asset Resilience Ratio
Hubei Biocause Pharmaceutical (000627) has an Asset Resilience Ratio of 0.78% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2023)
This chart shows how Hubei Biocause Pharmaceutical's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hubei Biocause Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.24 Billion | 0.78% |
| Total Liquid Assets | CN¥2.24 Billion | 0.78% |
Asset Resilience Insights
- Limited Liquidity: Hubei Biocause Pharmaceutical maintains only 0.78% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hubei Biocause Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Hubei Biocause Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
COFCO Capital Holdings Co Ltd
SHE:002423 |
Insurance - Life | 17.56% |
|
Samsung Life
KO:032830 |
Insurance - Life | 56.65% |
|
Mirae Asset Life Insurance Co Ltd
KO:085620 |
Insurance - Life | 37.10% |
|
Hanwha Life
KO:088350 |
Insurance - Life | 69.64% |
|
Manulife Holdings Bhd
KLSE:1058 |
Insurance - Life | 48.30% |
|
Mercuries Life Insurance Co Ltd
TW:2867 |
Insurance - Life | 0.73% |
|
Fubon Financial Holding Co Ltd
TW:2881 |
Insurance - Life | 0.92% |
|
Cathay Financial Holding Co Ltd
TW:2882 |
Insurance - Life | 3.32% |
Annual Asset Resilience Ratio for Hubei Biocause Pharmaceutical (2002–2023)
The table below shows the annual Asset Resilience Ratio data for Hubei Biocause Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.60% | CN¥1.80 Billion | CN¥301.94 Billion | -0.13pp |
| 2022-12-31 | 0.72% | CN¥2.08 Billion | CN¥288.60 Billion | -0.38pp |
| 2021-12-31 | 1.10% | CN¥2.91 Billion | CN¥263.90 Billion | -0.39pp |
| 2020-12-31 | 1.49% | CN¥3.56 Billion | CN¥239.40 Billion | +0.41pp |
| 2019-12-31 | 1.08% | CN¥2.21 Billion | CN¥205.27 Billion | -1.89pp |
| 2017-12-31 | 2.97% | CN¥4.16 Billion | CN¥140.42 Billion | +2.15pp |
| 2008-12-31 | 0.81% | CN¥16.08 Million | CN¥1.98 Billion | +0.57pp |
| 2007-12-31 | 0.24% | CN¥3.22 Million | CN¥1.32 Billion | +0.13pp |
| 2006-12-31 | 0.11% | CN¥1.34 Million | CN¥1.17 Billion | -0.01pp |
| 2002-12-31 | 0.12% | CN¥1.36 Million | CN¥1.09 Billion | -- |